Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial

Richard Furie(Hofstra University), Eric F. Morand(Monash University), Ian N Bruce(Versus Arthritis), Susan Manzi(Allegheny Health Network), Kenneth Kalunian(University of California, San Diego), Edward M Vital(Leeds Teaching Hospitals NHS Trust), Theresa Lawrence Ford(Georgia Urology), Ramesh K. Gupta(Baptist Memorial Hospital), Falk Hiepe(Charité - Universitätsmedizin Berlin), Mittermayer B. Santiago(Fundação Bahiana de Infectologia), Philip Z. Brohawn(AstraZeneca (United States)), Anna Berglind(AstraZeneca (Sweden)), Raj Tummala(AstraZeneca (United States))
The Lancet Rheumatology
November 11, 2019
10.1016/s2665-9913(19)30076-1
Cited by 467Open Access
Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis